Note: ArmaGen's revenues are gauged from an analysis of company filings.
ArmaGen has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
March 2, 2018
Complete list of funding rounds and total amounts in the Company Report
ArmaGen's Income Statement (based on Industry Averages)
$ Millions (Industry Average)
ArmaGen Revenue (Sales)
Cost of Goods Sold
Salaries and wages
Other Operating Expenses
Total Operating Expenses
EBIT (Earnings Before Interest and Taxes)
Trademark applications show the products and services that ArmaGen is developing and marketing.
ArmaGen doesn't have any recent trademark applications, indicating ArmaGen is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
ARMAGEN Pharmaceutical preparations and drug delivery compositions for the treatment of neurological, ocular, liver, spleen, lung and respiratory diseases and disorders
Patent applications show ArmaGen's intellectual property,
its current capabilities and future direction.
ArmaGen has applied for 16 patents since 2009.
ArmaGen's most recent patent was filed in April 2017 for Methods And Compositions For Increasing Alpha-l-iduronidase Activity In The Cns.Provided herein are methods and compositions for treating a subject suffering from a deficiency in Î±-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an Î±-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-Î±-L-Iduronidase fusion antibodies as described herein.
Complete list of patent applications
Determine whether ArmaGen grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof ArmaGen is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Competition: ArmaGen vs. Largest Competitors
A competitive analysis shows these companies are in the same general field as ArmaGen, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are in the same general field as ArmaGen and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.